| 摘要: |
| 目的 与大多数药物制剂一样,纳米制剂的性能可通过一系列体内与体外实验进行评价。其中,药物释放度反映了纳米制剂在体内外环境中的释放行为,是评估其安全性与有效性的关键参数之一。由于药物释放动力学的体内研究通常需要耗费大量时间、人力与费用,并涉及人体或动物实验,存在伦理与操作上的限制,因此,体外药物释放度测定作为纳米制剂性能评价的替代方法,越来越受到药物研发者的关注。本文将总结目前用于纳米药物递送系统体外药物释放度研究的常用检测方法。方法 调研近年来国内外文献,对常用检测方法进行对比分析。由于纳米制剂尚无统一的体外药物释放度标准测试方法,研究者通常采用多种技术手段进行评价,包括取样分离法、连续流动法、透析膜法及这些方法的组合,同时也涉及Franz扩散池法、切向流法等新兴技术。本文对这些方法的基本原理、实验装置、操作流程进行了描述,并重点比较了它们各自的优缺点与适用性。结果 取样分离法可直接测定药物释放量,装置要求相对简单,但操作过程较为繁琐,且在多次取样过程中存在药物损失或泄漏的风险;连续流动法具有取样方便、装置自动化和标准化程度高的优势,但系统较为复杂,成本较高;透析膜法装置和操作较为简便,但透析膜可能对药物释放产生扩散阻碍,尤其对与膜有吸附或结合的药物并不适用。此外,一些新兴方法(如实时监测技术)在理论上可实现药物释放的实时检测,但目前多局限于特定药物类型或制剂体系。总体而言,不同方法在数据准确性、操作便捷性、装置成本及适用范围等方面存在显著差异,各有优劣。结论 目前,纳米制剂的体外药物释放度测定尚无统一标准方法,实际研究中对方法的选择应综合考虑药物性质、载体类型及研究目的。未来,开发与体内释放行为具有良好相关性的体外释放评价方法,是纳米药物研发与质量控制的重要发展方向。在此基础上,进一步推动体外释放度测定技术的标准化、规范化,并结合多技术联合应用与先进检测技术,将有助于提升纳米药物体外评价的科学性、可靠性和转化效率,为其临床应用奠定基础。 |
| 关键词: 纳米药物 药物释放度 表征 质量研究 |
| DOI:10.13506/j.cnki.jpr.2025.12.012 |
| 基金项目:药品监管科学全国重点实验室课题(No.2023SKLDRS0109);国家药品监督管理局药品监管科学体系建设重点项目(No.RS2024H005) |
|
出版日期:2025-12-25
|
|
| Research progress on nanomedicines release testing methods |
| SUN Jiabei1,PENG Bo2,LIN Xiaoyang3,WU Jun2,HUANG Haiwei1 |
| (1.National Institutes for Food and Drug Control, Beijing 102629,China; 2.Beijing Tide Pharmaceutical Co.,Ltd, Beijing 100176,China; 3.Yantai Center for Food and Drug Control, Yantai 264670,China) |
| Abstract: |
| Objective Like most pharmaceutical formulations,the performance of nanopharmaceuticals can be evaluated through a variety of in vitro and in vivo experiments. Among these,drug release serves as a critical parameter that provides essential insights into the in vitro and in vivo behavior of nanopharmaceuticals, and is key to assessing their safety and efficacy. Due to the high cost, time consumption, labor intensity, and ethical concerns associated with in vivo drug release kinetic studies (which involve human or animal experimentation), in vitro drug release testing has gained increasing attention as a surrogate and complementary approach for evaluating nanopharmaceutical performance during drug development. Methods This review summarizes the commonly used in vitro drug release testing methods for nanodrug delivery systems. Given the absence of a universally standardized in vitro drug release assay for nanopharmaceuticals, a variety of techniques have been employed, including sample-and-separation methods, continuous flow methods, dialysis membrane-based methods, as well as combinations of these three. Additionally, emerging approaches such as the Franz diffusion cell method and tangential flow filtration (TFF) method are also discussed. For each method, the underlying principles, experimental setups, and key advantages and disadvantages are described and compared.Results The sample-and-separation method allows for direct measurement of drug release, with relatively simple equipment requirements, but it involves tedious sampling procedures and carries a risk of drug loss or leakage. The continuous flow method offers more convenient sampling and higher levels of automation and standardization, but the technique is relatively complex and costly. The dialysis membrane method is simple in both setup and sampling, yet it is limited by the potential barrier effect of the dialysis membrane on drug diffusion and may not be suitable for drugs that bind to the membrane.Emerging methods, such as real-time monitoring techniques, show promise but may be applicable only to certain types of drugs or formulations. Each method presents distinct strengths and weaknesses in terms of accuracy, reproducibility, practicality, and suitability for different nanopharmaceutical systems. Conclusion There is currently no one-size-fits-all in vitro drug release method for nanopharmaceuticals, and the choice of method should be carefully tailored based on the properties of the drug, the delivery system, and the intended application. Looking ahead, the development of in vitro drug release assays that better correlate with in vivo release behavior represents a crucial direction for future research. Establishing standardized protocols, improving method robustness, and integrating advanced technologies will enhance the reliability of in vitro testing and support the rational design, quality control, and clinical translation of nanopharmaceuticals. |
| Key words: Nanomedicines Drug release Characterization Quality research |